Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.
Reinisch W, Colombel JF, D'Haens G, Sandborn WJ, Rutgeerts P, Geboes K, Petersson J, Eichner S, Zhou Q, Robinson AM, Read HA, Thakkar R. Reinisch W, et al. Among authors: petersson j. J Crohns Colitis. 2017 Apr 1;11(4):425-434. doi: 10.1093/ecco-jcc/jjw178. J Crohns Colitis. 2017. PMID: 27815351 Free PMC article. Clinical Trial.
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G. Colombel JF, et al. Among authors: petersson j. Lancet. 2017 Dec 23;390(10114):2779-2789. doi: 10.1016/S0140-6736(17)32641-7. Epub 2017 Oct 31. Lancet. 2017. PMID: 29096949 Clinical Trial.
Clinical disease activity in the CALM study - Authors' reply.
Colombel JF, Panaccione R, Petersson J, Robinson AM, D'Haens G. Colombel JF, et al. Among authors: petersson j. Lancet. 2018 Apr 14;391(10129):1482. doi: 10.1016/S0140-6736(18)30775-X. Lancet. 2018. PMID: 29676280 No abstract available.
Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials.
Panaccione R, Sandborn WJ, D'Haens G, Wolf DC, Berg S, Maa JF, Petersson J, Robinson AM. Panaccione R, et al. Among authors: petersson j. J Crohns Colitis. 2018 Jul 30;12(8):930-938. doi: 10.1093/ecco-jcc/jjy050. J Crohns Colitis. 2018. PMID: 29697818 Free PMC article.
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry.
DʼHaens G, Reinisch W, Panaccione R, Satsangi J, Petersson J, Bereswill M, Arikan D, Perotti E, Robinson AM, Kalabic J, Alperovich G, Thakkar R, Loftus EV. DʼHaens G, et al. Among authors: petersson j. Am J Gastroenterol. 2018 Jun;113(6):872-882. doi: 10.1038/s41395-018-0098-4. Epub 2018 Jun 5. Am J Gastroenterol. 2018. PMID: 29867173
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.
Panaccione R, Colombel JF, Travis SPL, Bossuyt P, Baert F, Vaňásek T, Danalıoğlu A, Novacek G, Armuzzi A, Reinisch W, Johnson S, Buessing M, Neimark E, Petersson J, Lee WJ, D'Haens GR. Panaccione R, et al. Among authors: petersson j. Gut. 2020 Apr;69(4):658-664. doi: 10.1136/gutjnl-2019-318256. Epub 2019 Jul 8. Gut. 2020. PMID: 31285357 Free PMC article. Clinical Trial.
261 results